Infection with Vancomycin-Resistant Staphylococcus aureus Containing the vanA Resistance Gene
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Vancomycin-resistant S. aureus was cultured from the exit site of a temporary dialysis catheter of a patient with diabetes, peripheral vascular disease, and persistent foot ulcers. The organism carried the vanA resistance gene, which may have come from the vancomycin-resistant Enterococcus faecalis that was also isolated from the patient, who had received vancomycin for several weeks.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Increasing rates of oxacillin-resistant S aureus or MRSA isolates in both hospital and community settings and the recovery of clinical S aureus isolates both partially and fully 138,139 resistant to vancomycin have complicated the treatment of S aureus IE.”
In the citing paper
“the recovery of clinical S aureus isolates both partially and fully 138,139 resistant to vancomycin have complicated the treatment of S aureus IE.”
In the citing paper
“and is especially prevalent in North America.6,138,139”
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Medical Entomology and Zoology · Cited by 17,248
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Diagnostic molecular microbiology : principles and applications
Persing, D. H. (1993) · ASM Press eBooks · Cited by 1,311
Emergence of Vancomycin Resistance in Staphylococcus aureus
Smith, T. L., Pearson, M. L., Wilcox, K. R., Cruz, C., Lancaster, M. V., Robinson-Dunn, B., Tenover, F. C., Zervos, M. J., Band, J. D., White, E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400701 · Cited by 1,088
Self-citation(2001) · PsycEXTRA Dataset · doi:10.1037/e548252006-001 · Cited by 1,018
Noble, W. C., Virani, Z., & Cree, R. G. A. (1992) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1992.tb05089.x · Cited by 627
Arthur, M., Molinas, C., Depardieu, F., & Courvalin, P. (1993) · Journal of Bacteriology · doi:10.1128/jb.175.1.117-127.1993 · Cited by 603
Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus
Bannerman, T. L., Hancock, G. A., Tenover, F. C., & Miller, J. M. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.3.551-555.1995 · Cited by 550
Self-citationCharacterization of glycopeptide-resistant enterococci from U.S. hospitals
Clark, N. C., Cooksey, R. C., Hill, B. C., Swenson, J. M., & Tenover, F. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.11.2311 · Cited by 395
Self-citationApplication of pulsed-field gel electrophoresis to molecular epidemiology
Maslow, J. N. (1993) · Medical Entomology and Zoology · Cited by 382
Research works printed but not linked: 7
- 1997, MMWR Morb Mortal Wkly Rep, 46, 624
- 2000, MMWR Morb Mortal Wkly Rep, 48, 1165
- 2002, MMWR Morb Mortal Wkly Rep, 51, 565
- Kloos WE, Bannerman TL. Staphylococcus and Micrococcus. In: Murray PR, ed. Manual of clinical microbiology. 7th ed. Washington, D.C.: ASM Press, 1999:264-82.
- 2001, MMWR Morb Mortal Wkly Rep, 50, 1
- 1995, MMWR Morb Mortal Wkly Rep, 44, 1
- 1997, MMWR Morb Mortal Wkly Rep, 46, 626
Cited by
Items 201–300 of 1,000
Su, Y., Ma, L., Wen, Y., Wang, H., & Zhang, S. (2014) · Molecules · doi:10.3390/molecules190812630 · Cited by 94
“Natural products from higher plants have traditionally been regarded as an important source of antimicrobial agents and have attracted extensive attention in fundamental and clinic applications [5,6].”
BackgroundMethicillin-Resistant Staphylococcus aureus Infection and Treatment Options
Chalmers, S. J., & Wylam, M. E. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9849-4_16 · Cited by 102
Virulence attributes of successful methicillin-resistant Staphylococcus aureus lineages
Jiang, J.-H., Cameron, D. R., Nethercott, C., Aires-de-Sousa, M., & Peleg, A. Y. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00148-22 · Cited by 92
Nakonieczna, J., Michta, E., Rybicka, M., Grinholc, M., Gwizdek‐Wiśniewska, A., & Bielawski, K. P. (2010) · BMC Microbiology · doi:10.1186/1471-2180-10-323 · Cited by 99
“aureus (MRSA) strains, constituting 50% of hospital-aquired isolates as well as emerging vancomycin-resistant variants, isolated from some hospital settings [2].”
BackgroundEpidemiology and control of antibiotic resistance in the intensive care unit
Carlet, J. M., Ali, A. B., & Chalfine, A. (2004) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000136927.29802.68 · Cited by 92
Comparative Genomics and Transduction Potential of Enterococcus faecalis Temperate Bacteriophages
Yasmin, A., Kenny, J. G., Shankar, J., Darby, A. C., Hall, N., Edwards, C., & Horsburgh, M. J. (2009) · Journal of Bacteriology · doi:10.1128/jb.01293-09 · Cited by 105
Antibiotic resistance propagation through probiotics
Daniali, M., Nikfar, S., & Abdollahi, M. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1825682 · Cited by 90
Mahros, M. A., Abd‐Elghany, S. M., & Sallam, K. I. (2021) · International Journal of Food Microbiology · doi:10.1016/j.ijfoodmicro.2021.109165 · Cited by 97
Salem-Bekhit, M. M., Moussa, I., Muharram, M., Alanazy, F., & Hefni, H. (2012) · Indian Journal of Medical Microbiology · doi:10.4103/0255-0857.93032 · Cited by 89
Lebreton, F., van Schaik, W., Sanguinetti, M., Posteraro, B., Torelli, R., Bras, F. L., Verneuil, N., Zhang, X., Giárd, J.-C., Dhalluin, A., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002834 · Cited by 91
“Reports on the transfer of vancomycin resistance from enterococci to methicillin-resistant Staphylococcus aureus stress the need to better understand the molecular epidemiology, as well as the transmissibility and virulence of enterococci, to control further spread and develop treatment and eradication strategies [4,5…”
BackgroundCasey, A. L., Lambert, P. A., & Elliott, T. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(07)72175-1 · Cited by 133
Prevention and control of methicillin-resistant Staphylococcus aureus infections
Farr, B. M. (2004) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000136926.52673.cd · Cited by 88
Lateral gene transfer between prokaryotes and eukaryotes
Sieber, K. B., Bromley, R. E., & Hotopp, J. C. D. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.02.009 · Cited by 97
“More recently, bacteria have acquired deadly combinations of antibiotic resistance genes via LGT, such as vancomycin-resistant, methicillin-resistant Staphylococcus aureus [7] (Figure 1).”
BackgroundFrankel, M. B., Hendrickx, A. P. A., Missiakas, D. M., & Schneewind, O. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.258863 · Cited by 80
Methicillin-resistant and susceptible Staphylococcus aureus: tolerance, immune evasion and treatment
Parsons, J. B., Mourad, A., Conlon, B. P., Kielian, T., & Fowler, V. G. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01226-2 · Cited by 105
“VRSA relies upon the acquisition of the vanA operon, typically from a strain of vancomycin-resistant Enterococcus faecalis 91 .”
Welte, T., & Pletz, M. W. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.06.045 · Cited by 94
“containing VRSA was isolated from a dialysis patient in Michigan, USA [36]; such isolates have since been detected throughout the world although the incidence remains low.”
BackgroundRehm, S. J., & Tice, A. D. (2010) · Clinical Infectious Diseases · doi:10.1086/653518 · Cited by 85
Acquired Vancomycin Resistance in Clinically Relevant Pathogens
Werner, G., Strommenger, B., & Witte, W. (2008) · Future Microbiology · doi:10.2217/17460913.3.5.547 · Cited by 82
“aureus (VRSA) was isolated from a dialysis patient in Michigan, USA [78,79].”
BackgroundA humanized monoclonal antibody targeting Staphylococcus aureus
Patti, J. M. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.08.015 · Cited by 83
Yang, Y., Severin, A. I., Chopra, R., Krishnamurthy, G., Singh, G., Hu, W. K., Keeney, D. R., Svenson, K., Petersen, P. J., Labthavikul, P., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.556-564.2006 · Cited by 83
Cameron, D. R., Howden, B. P., & Peleg, A. Y. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir473 · Cited by 81
Oh, D., Sun, J., Shirazi, A. N., LaPlante, K. L., Rowley, D. C., & Parang, K. (2014) · Molecular Pharmaceutics · doi:10.1021/mp5003027 · Cited by 85
Shekarabi, M., Hajikhani, B., Chirani, A. S., Fazeli, M., & Goudarzi, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183607 · Cited by 83
Vancomycin-resistant enterococci: consequences for therapy and infection control
Mascini, E. M., & Bonten, M. J. M. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01164.x · Cited by 83
Hawser, S., Bouchillon, S. K., Hoban, D. J., Dowzicky, M. J., & Babinchak, T. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.10.029 · Cited by 82
“[8] Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, et al.”
BackgroundO’Toole, R., Leong, K. W. C., Cumming, V., & van Hal, S. J. (2023) · Research in Microbiology · doi:10.1016/j.resmic.2023.104046 · Cited by 94
Ojala, V., Laitalainen, J., & Jalasvuori, M. (2013) · Evolutionary Applications · doi:10.1111/eva.12076 · Cited by 82
“…common nosocomial pathogens like Escherichia coli , Klebsiella pneumoniae (Ha-rajly et al. 2010) and Staphylococcus aureus (Lyon and Skur-ray 1987; Chang et al. 2003; Weigel et al. 2003), the presence of plasmid-dependent phages could hypothetically give antibiotics and the immune system more…”
Shutt, C. K., Pounder, J. I., Page, S. R., Schaecher, B. J., & Woods, G. L. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.3.1187-1192.2005 · Cited by 98
Clark, N. C., Weigel, L. M., Patel, J. B., & Tenover, F. C. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.1.470-472.2005 · Cited by 82
Self-citationRay, A. J., Pultz, N. J., Bhalla, A., Aron, D. C., & Donskey, C. J. (2003) · Clinical Infectious Diseases · doi:10.1086/377451 · Cited by 82
Mechanisms of antimicrobial resistance among hospital-associated pathogens
Khan, A., Miller, W. R., & Arias, C. A. (2018) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2018.1456919 · Cited by 92
“aureus (VRSA), attributed to the acquisition of the vanA gene cluster from vancomycin-resistant enterococci (VRE), was reported in the USA (MIC >100 mg/L) [133,134].”
BackgroundFarman, M., Yasir, M., Al-Hindi, R. R., Farraj, S. A., Jiman-Fatani, A. A., Alawi, M., & Azhar, E. I. (2019) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-019-0508-4 · Cited by 93
Mishra, N. N., Yang, S.-J., Chen, L., Muller, C., Saleh-Mghir, A., Kuhn, S., Peschel, A., Yeaman, M. R., Nast, C. C., Kreiswirth, B. N., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071151 · Cited by 81
Isolation of soil Streptomyces as source antibiotics active against antibiotic-resistant bacteria
Ceylan, Ö., Ökmen, G., & Uğur, A. (2008) · Eurasian Journal of Biosciences · Cited by 98
Chang, Y., Chen, W.-C., Hsieh, P., Chen, D. W., Lee, M. S.-S., Shih, H., & Ueng, S. W. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05312-11 · Cited by 92
“However, reports of vancomycin-intermediate S. aureus (VISA), first isolated in Japan in 1997 (10), and vancomycin-resistant S. aureus in the United States (4) caused widespread alarm.”
BackgroundMortin, L. I., Li, T., Van Praagh, A. D. G., Zhang, S., Zhang, X.-X., & Alder, J. D. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00738-06 · Cited by 80
“aureus (7, 9) and, as demonstrated in the current study, is a more rapidly bactericidal alternative to vancomycin against MRSA and MSSA in vivo.”
BackgroundRole of Infectious Diseases Consultants in Management of Antimicrobial Use in Hospitals
Sunenshine, R. H., Liedtke, L. A., Jernigan, D. B., Strausbaugh, L. J., & the Infectious Diseases Society of America Emerging Infections Network (2004) · Clinical Infectious Diseases · doi:10.1086/382358 · Cited by 80
An, J., Zuo, G., Hao, X., Wang, G. C., & Li, Z. S. (2011) · Phytomedicine · doi:10.1016/j.phymed.2011.02.013 · Cited by 80
Amyes, S. G. B. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(07)72177-5 · Cited by 90
Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections
Eisenstein, B. I. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.9.1159 · Cited by 85
“aureus [VRSA] and vancomycin-resistant enterococci [VRE]) [3-15].”
Daptomycin: A novel cyclic lipopeptide antimicrobial
Schriever, C. A., Fernández, C., Rodvold, K. A., & Danziger, L. H. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.11.1145 · Cited by 87
Kim, H. K., Kim, H., Schneewind, O., & Missiakas, D. M. (2011) · The FASEB Journal · doi:10.1096/fj.11-187963 · Cited by 85
Reyes, R., Ahn, R., Thurber, K. A., & Burke, T. F. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4496-1_4 · Cited by 100
“Only a few cases of VRSA have been reported in the USA to date [ 100 ] , Aedes mosquitoes thrive in urban environments; Anophales mosquitoes do not.”
BackgroundDenis, O., Deplano, A., Nonhoff, C., Hallin, M., Ryck, R. D., Vanhoof, R., Mendonça, R. D., & Struelens, M. J. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00272-06 · Cited by 84
“The requirement for effective new agents to treat MRSA infections is becoming increasingly apparent due to the emergence of strains with reduced susceptibility to glycopeptides and, more recently, of strains resistant to vancomycin by transfer of the vanA gene from Enterococcus faecalis (3, 15).”
BackgroundXu, L., Huang, H., Wei, W., Zhong, Y., Tang, B., Yuan, H., Zhu, L., Huang, W., Ge, M., Yang, S., et al. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-363 · Cited by 81
“Alphabetic n development of new antibiotics against these pathogens [2-5].”
BackgroundMaor, Y., Rahav, G., Belausov, N., Ben-David, D., Smollan, G., & Keller, N. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01262-06 · Cited by 75
“Up till April 2006 only four cases with infections due to VRSA have been reported, which exhibit the vanA gene complex found in vancomycin-resistant enterococci (2, 3, 12).”
BackgroundTang, H.-J., Chen, C.-C., Cheng, K.-C., Toh, H.-S., Su, B.-A., Chiang, S.-R., Ko, W.-C., & Chuang, Y.-C. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr535 · Cited by 74
Hassan, D., Omolo, C. A., Fasiku, V. O., Mocktar, C., & Govender, T. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.01.019 · Cited by 76
Tran, N. N., Morrisette, T., Jorgensen, S. C. J., Orench‐Benvenutti, J. M., & Kebriaei, R. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2806 · Cited by 83
Nanoscale Particle Therapies for Wounds and Ulcers
Cortivo, R., Vindigni, V., Iacobellis, L., Abatangelo, G., Pinton, P., & Zavan, B. (2010) · Nanomedicine · doi:10.2217/nnm.10.32 · Cited by 77
The 2009 Garrod Lecture: The evolution of antimicrobial resistance: a Darwinian perspective
SYKES, R. B. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq217 · Cited by 74
Xiong, Y. Q., Abdelhady, W., Deslandes, A., Rey, A., Fraisse, L., Kristensen, H., Yeaman, M. R., & Bayer, A. S. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00453-11 · Cited by 74
Chakraborty, S. P., Mahapatra, S. K., Bal, M., & Roy, S. (2011) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 107
Troidle, L. K., Gorban‐Brennan, N., Kliger, A. S., & Finkelstein, F. O. (2003) · Seminars in Dialysis · doi:10.1046/j.1525-139x.2003.16095.x · Cited by 89
Warren, D. K., Nitin, A., Hill, C., Fraser, V. J., & Kollef, M. H. (2004) · Infection Control and Hospital Epidemiology · doi:10.1086/502357 · Cited by 74
Domanski, P. J., Patel, P. R., Bayer, A. S., Zhang, L., Hall, A. E., Syribeys, P. J., Gorovits, E., Bryant, D., Vernachio, J. H., Hutchins, J. T., et al. (2005) · Infection and Immunity · doi:10.1128/iai.73.8.5229-5232.2005 · Cited by 74
“More recently, reports documenting an increase in community-associated infections caused by methicillin-resistant Staphylococcus aureus (MRSA) (13) and vancomycin-resistant S. aureus strains in patients from Michigan (3), Pennsylvania (1), and New York (2) have served to further highlight the increasing dilemma clinic…”
BackgroundMolecular epidemiology of clinically significant antibiotic resistance genes
Hawkey, P. M. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707632 · Cited by 73
“The second wave of MRSA infections following the initial appearance started in the late 1970s, first in Australia, the Irish Republic and USA, since when rates of MRSA have increased in virtually all countries with a few notable exceptions such as the Netherlands and Denmark (Diekema et al., 2001).”
BackgroundInfluentialKim, H. B., Park, W. B., Lee, J. H., Kang, C., Bang, J.-W., Kim, H. B., Kim, N.-J., Kim, E.-C., Oh, M., & Choe, K. W. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01294.x · Cited by 78
“aureus with enhanced resistance to vancomycin is associated with prolonged treatment with vancomycin or glycopeptides [3,4].”
BackgroundMergenhagen, K. A., & Borton, A. R. (2014) · Journal of Pharmacy Practice · doi:10.1177/0897190014546114 · Cited by 73
“Decreased susceptibility of S aureus to vancomycin was first reported more than 15 years ago, with the first case report of fully vancomycin-resistant S aureus (VRSA) infection from Michigan in 2002.(9) Increasing minimum inhibitory concentrations (MICs) of S aureus to vancomycin have been observed in numerous clinica…”
BackgroundZacharioudakis, I. M., Zervou, F. N., Ziakas, P. D., Rice, L. B., & Mylonakis, E. E. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.05.016 · Cited by 83
Jones, R. C., Deck, J., Edmondson, R. D., & Hart, M. E. (2008) · Journal of Bacteriology · doi:10.1128/jb.00383-08 · Cited by 70
McCallum, N., Karaüzüm, H., Getzmann, R., Bischoff, M., Majcherczyk, P. A., Berger‐Bächi, B., & Landmann, R. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00073-06 · Cited by 79
“Although the MIC for NM67 was above the teicoplanin breakpoint for intermediate level resistance (25), we define NM67 as being glycopeptide intermediate resistant because of the genetic basis of its resistance mechanism, which is distinct from the van gene-based resistance of clinical vancomycin-resistant S. aureus (…”
BackgroundHerold, K., Gollmick, F. A., Groth, I., Roth, M., Menzel, K., Möllmann, U., Gräfe, U., & Hertweck, C. (2005) · Chemistry - A European Journal · doi:10.1002/chem.200500320 · Cited by 72
Daptomycin – a novel antibiotic against Gram-positive pathogens
LaPlante, K. L., & Rybak, M. J. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.11.2321 · Cited by 72
Cole, J., Aberdein, J., Jubrail, J., & Dockrell, D. H. (2014) · Advances in microbial physiology/Advances in Microbial Physiology · doi:10.1016/bs.ampbs.2014.08.004 · Cited by 81
Noto, M. J., Fox, P. M., & Archer, G. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01164-07 · Cited by 87
“As a result, S. aureus strains with reduced susceptibility to vancomycin are emerging (6, 10 , 22, 24).”
BackgroundEvaluation of S. aureus ID, a New Chromogenic Agar Medium for Detection of Staphylococcus aureus
Perry, J. D., Rennison, C., Butterworth, L. A., Hopley, A. L. J., & Gould, F. K. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.12.5695-5698.2003 · Cited by 71
Fenton, C., Keating, G. M., & Curran, M. P. (2004) · Drugs · doi:10.2165/00003495-200464040-00009 · Cited by 71
Selective pressures during chronic infection drive microbial competition and cooperation
Baishya, J., & Wakeman, C. A. (2019) · npj Biofilms and Microbiomes · doi:10.1038/s41522-019-0089-2 · Cited by 70
Methicillin-Resistant Staphylococcus Aureus Infections
Taylor, A. R. (2013) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2013.06.002 · Cited by 82
Saadat, S., Solhjoo, K., Norouz-nejad, M., & Kazemi, A. (2014) · Oman Medical Journal · doi:10.5001/omj.2014.90 · Cited by 79
Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens
Streit, J. M., Sader, H. S., Fritsche, T. R., & Jones, R. N. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2005.03.004 · Cited by 69
“Novel and increasing resistance mechanisms among Gram-positive pathogens are presenting challenges to existing antimicrobials (Chang et al., 2003; Meka and Gold, 2004).”
BackgroundKalashnikov, M., Lee, J. C., Campbell, J., Sharon, A., & Sauer-Budge, A. F. (2012) · Lab on a Chip · doi:10.1039/c2lc40531h · Cited by 70
Tedizolid (TR-701): a new oxazolidinone with enhanced potency
Kanafani, Z. A., & Corey, G. R. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.660250 · Cited by 73
“aureus (VRSA) strains [11,12] have complicated the treatment of staphylococcal infections.”
BackgroundNasal Carriage of Methicillin-ResistantStaphylococcus aureusAmong Hospital Staff and Outpatients
Cesur, S., & Çokça, F. (2004) · Infection Control and Hospital Epidemiology · doi:10.1086/502371 · Cited by 83
Chatterjee, A., Willett, J. L. E., Dunny, G. M., & Duerkop, B. A. (2021) · PLOS Genetics · doi:10.1371/journal.pgen.1009204 · Cited by 66
Semi-synthetic glycopeptide antibacterials
Judice, J. K., & Pace, J. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.08.067 · Cited by 68
Ziesmer, J., Tajpara, P., Hempel-Højgaard, N.-J., Ehrström, M., Melican, K., Eidsmo, L., & Sotiriou, G. A. (2021) · Advanced Materials Technologies · doi:10.1002/admt.202001307 · Cited by 68
Phytochemicals with activity against methicillin-resistant Staphylococcus aureus
Liang, M., Ge, X., Xua, H., Ma, K., Zhang, W., Zan, Y., Efferth, T., Xue, Z., & Hua, X. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154073 · Cited by 70
Targeting MgrA-Mediated Virulence Regulation in Staphylococcus aureus
Sun, F., Zhou, L., Zhao, B.-C., Deng, X., Cho, H., Yi, C., Jian, X., Song, C., Luan, C.-H., Bae, T., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.05.014 · Cited by 67
Pfaller, M. A., Sader, H. S., & Jones, R. N. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2006.10.007 · Cited by 67
“aureus (VISA and VRSA, respectively) (Chang et al., 2003; Hiramatsu, 2001; Liu and Chambers, 2003) and of MRSA and enterococci resistant to linezolid (Gonzales et al.”
BackgroundClinical Characteristics of Linezolid-Resistant Staphylococcus aureus Infections
Peeters, M. J., & Sarria, J. C. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200508000-00007 · Cited by 67
Pan, S., Wang, J., Chen, Y., Chang, Y.-Y., Chen, M., & Chang, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047297 · Cited by 67
“Clinical impacts of VRE include the limited availability of drugs to treat VRE infections and the ability of VRE to transfer the genetic determinant for vancomycin resistance to other Gram-positive pathogens, such as Staphylococcus aureus [2–3].”
BackgroundSelf-citationRavipaty, S., & Reilly, J. P. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900494-mcp200 · Cited by 65
Genome-wide dynamics of a bacterial response to antibiotics that target the cell envelope
Hesketh, A. R., Hill, C. H., Mokhtar, J., Novotna, G. B., Tran, N. T., Bibb, M. J., & Hong, H. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-226 · Cited by 74
“The increase in the number of cases of methicillin-resistant Staphylococcus aureus (MRSA), and the emergence of vancomycinresistant MRSA in hospital-acquired infections are two such examples [3-6].”
BackgroundPre-clinical experience with daptomycin
Hawkey, P. M. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn367 · Cited by 73
Anti-methicillin Resistant Staphylococcus aureus (MRSA) Compounds Isolated from Laurus nobilis
Otsuka, N., Liu, M.-H., Shiota, S., Ogawa, W., Kuroda, T., Hatano, T., & Tsuchiya, T. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.1794 · Cited by 78
Molecular Basis of Non-β-Lactam Antibiotics Resistance in Staphylococcus aureus
Lade, H. S., Joo, H., & Kim, J. (2022) · Antibiotics · doi:10.3390/antibiotics11101378 · Cited by 74
Griffith, B. R., Krepel, C. J., Fu, X., Blanchard, S., Ahmed, A., Edmiston, C. E., & Thorson, J. S. (2007) · Journal of the American Chemical Society · doi:10.1021/ja068602r · Cited by 70
Zuo, G., Li, Y., Han, J. H., Wang, G.-C., Zhang, Y., & Bian, Z. (2012) · Molecules · doi:10.3390/molecules170910322 · Cited by 66
“aureus (VRSA) [2].”
O'May, G. A., Reynolds, N., Smith, A. R., Kennedy, A., & Macfarlane, G. T. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.7.3059-3065.2005 · Cited by 65
“occur in these organisms (9) and (ii) vancomycin-resistant enterococci cause problems in hospitals, both as pathogens (37) and as vectors for the spread of vancomycin resistance to staphylococci (6, 39).”
BackgroundParallel Genomics Uncover Novel Enterococcal-Bacteriophage Interactions
Chatterjee, A., Willett, J. L. E., Nguyen, U. T., Monogue, B., Palmer, K. L., Dunny, G. M., & Duerkop, B. A. (2020) · mBio · doi:10.1128/mbio.03120-19 · Cited by 61
Lauderdale, T.-L. Y., Shiau, Y., Wang, H., Lai, J., Huang, I., Chen, P., Chen, H., Lai, S., Liu, Y., & Ho, M. (2006) · Environmental Microbiology · doi:10.1111/j.1462-2920.2006.01189.x · Cited by 63
Micrococcin P1: Structure, biology and synthesis
Ciufolini, M. A., & Lefranc, D. (2010) · Natural Product Reports · doi:10.1039/b919071f · Cited by 63
Li, Y., Su, T., Zhang, Y., Huang, X., Li, J., & Li, C. (2014) · Drug Delivery · doi:10.3109/10717544.2014.880756 · Cited by 67
“Vancomycin was once considered to be the last effective treatment for MRSA infections, but the emergence of vancomycin-resistant strains in recent decades has reduced MRSA susceptibility to this antibacterial agent (Voorn et al., 1994; Hiramatsu et al., 1997; Goldrick, 2002; Chang et al., 2003).”
BackgroundAbdelhady, W., Bayer, A. S., Seidl, K., Nast, C. C., Kiedrowski, M. R., Horswill, A. R., Yeaman, M. R., & Xiong, Y. Q. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02073-12 · Cited by 66
“aureus [VRSA]) (3), and (ii) its ability to form biofilms on both native tissues and implanted biomaterials (2).”
BackgroundYanagihara, K., Tashiro, M., Fukuda, Y., Ohno, H., Higashiyama, Y., Miyazaki, Y., Hirakata, Y., Tomono, K., Mizuta, Y., Tsukamoto, K., et al. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki416 · Cited by 69
“aureus first appeared in the USA in 2002.(7) Community-acquired MRSA is also becoming an important public health problem.”
BackgroundHemodialysis-Associated Infections
Nguyen, D. B., Arduino, M. J., & Patel, P. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52978-5.00025-2 · Cited by 74
Revealing the Mechanisms of Synergistic Action of Two Magainin Antimicrobial Peptides
Bechinger, B., Juhl, D. W., Glattard, E., & Aisenbrey, C. (2020) · Frontiers in Medical Technology · doi:10.3389/fmedt.2020.615494 · Cited by 67
“During recent years the rapid increase in multiresistant pathogens (19) has brought back research on AMPs (20, 21), because their mechanisms of action has been shown to be less prone to microbial resistance when compared to conventional treatments (2, 22, 23).”
BackgroundHenderson, D. K. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.04.002 · Cited by 62
Metadata
- Authors
- Chang, S., Sievert, D. M., Hageman, J. C., Boulton, M. L., Tenover, F. C., Downes, F. P., Shah, S., Rudrik, J. T., Pupp, G. R., Brown, W. J., Cardo, D., & Fridkin, S. K.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Michigan Department of Health and Human Services (US)
- Wayne State University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-03
- Volume
- 348
- Issue
- 14
- Pages
- 1342-1347
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2068037991
- Semantic Scholar
- f0afb59f819a65ada63076a36807f63502c4437d
- Cited by
- 1,095
- References
- 18
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 24 · 2023: 28 · 2022: 24 · 2021: 35 · 2020: 29 · 2019: 39 · 2018: 28 · 2017: 29 · 2016: 28 · 2015: 55 · 2014: 54 · 2013: 51 · 2012: 65
- FWCI
- 54.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Microbiology (medical) › Infections and bacterial resistance
- Keywords
- vancomycin-resistant Staphylococcus aureus, vanA gene, vancomycin resistance, diabetes mellitus, peripheral vascular disease, foot ulcer, vancomycin-resistant Enterococcus faecalis, antibiotic resistance transfer, catheter-related infection
- MeSH terms
- Adult, Catheterization, Debridement, Female, Renal Dialysis, Humans, Staphylococcal Infections, Staphylococcus aureus, Vancomycin, Contact Tracing, Diabetic Foot, Vancomycin Resistance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.